Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Income from Continuing Operations data on record, last reported at 118239000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 49.74% year-over-year to 118239000.0; the TTM value through Dec 2025 reached 340944000.0, down 26.67%, while the annual FY2025 figure was 340944000.0, 26.45% down from the prior year.
  • Income from Continuing Operations reached 118239000.0 in Q4 2025 per VRDN's latest filing, down from 35058000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 14134000.0 in Q3 2021 and bottomed at 118239000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 52853950.0, with a median of 48101000.0 recorded in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 68.11% in 2021, down 177.74% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 28946000.0 in 2021, then tumbled by 58.17% to 45785000.0 in 2022, then tumbled by 45.61% to 66667000.0 in 2023, then fell by 18.44% to 78961000.0 in 2024, then plummeted by 49.74% to 118239000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 118239000.0 in Q4 2025, 35058000.0 in Q3 2025, and 100735000.0 in Q2 2025.